novo nordisk glp-1 patent litigation drops lawsuit against Hims & Hers over off-brand weight loss medications, enter collaboration Novo Nordisk Drops Hims &

Nor-1, a novel incretin-responsive regulator of insulin genes and insulin secretion

Linagliptin, however, uses a distinct elimination route, as the majority of the drug is eliminated through the hepatobiliary system and, thus, is more favorable in cases of renal dysfunction [31]

Telehealth company Hims & Hers pulled a less expensive oral version of Wegovy after lawsuits from Novo Nordisk and rising regulatory scrutiny

For anyone looking for a natural alternative to traditional GLP-1 solutions, especially if injections aren't an option or you're seeking an over-the-counter supplement, this could be worth exploring